Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1046 results
September 2018
-
Media ReleaseWorld's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetimeFrom a sample of over 10,000 adults, 62% are worried that they may develop Alzheimer's disease and 91% believe the solution to tackling diseases lies in medical research[1] 79% are willing…
-
Media ReleaseLaunch of Alcon Experience Academy Reinforces Commitment to Training and Education for Eye Care ProfessionalsAlcon Experience Academy serves as umbrella for industry-leading training and educational resources for all eye care professionals New website houses a robust library of more than 500 videos,…
-
Media ReleaseNovartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patientsReal-world evidence confirms Cosentyx® efficacy and safety consistent with previously reported clinical studies[1]-[4] Novartis presents a large program of real-world evidence at the 27th…
-
Media ReleaseNovartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MSTreatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects…
-
Media ReleaseNovartis survey shows psoriasis patients want treatment effect beyond clear skinNew patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Media ReleaseAlcon confirms commitment to Switzerland ahead of proposed spinoff from NovartisGlobal headquarters to be co-located in Geneva alongside Alcon's Europe, Middle East and Africa regional office The listed Alcon company will be incorporated in Fribourg, where Alcon already has…
-
Key ReleaseNovartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to AurobindoNovartis to focus Sandoz division in US on higher growth areas and will sell selected portions of the Sandoz US portfolio to Aurobindo Pharma USA Inc. Agreement comprises the Sandoz US generic…
August 2018
-
Media ReleaseEuropean Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanomaApproval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III melanoma patients More than 50% of stage III melanoma…
-
Key ReleaseAlcon announces voluntary global market withdrawal of CyPass Micro-Stent for surgical glaucomaDecision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
-
Media ReleaseNovartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
-
Media ReleaseNovartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episodeTRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1…
-
Key ReleaseSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutationSOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
Pagination
- ‹ Previous page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- …
- 88
- › Next page